President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity treatments Zepbound and Wegovy. Here’s what we know.
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.
Lower prices for 15 drugs, including Ozempic and Wegovy, are expected to be announced by the end of the month. The price ...
Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...
The deal is expected to lower the price of some obesity drugs to $149 per month in certain cases, according to reports.
Health and Me on MSN
Wegovy and Zepbound Weight Loss Drug Prices May Soon Fall In The US: Here’s What You Should Know
Eli Lilly and Novo Nordisk may soon slash the prices of their leading weight loss drugs, Wegovy and Zepbound, under a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback